ClinicalTrials.gg
TerminatedNCT05514717Updated Jun 18, 2026

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

A Phase 1 interventional study of XMT-2056 in HER2-positive Breast Cancer, HER2-positive Gastric Cancer and HER2-positive Non-Small Cell Lung Cancer, sponsored by Day One Biopharmaceuticals, Inc.. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Day One Biopharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Development discontinued.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

Read the detailed description

The first-in-human (FIH) study of XMT-2056 is a Phase 1, open-label study of XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing HER2. The XMT-2056 monotherapy trial will consist of dose escalation (DES) and expansion (EXP) parts.

DES will be the dose-finding portion of the study to assess the safety and tolerability of XMT-2056 and determine the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D). The RP2D will be determined based on the totality of the clinical data, including safety and preliminary anti-tumor effect, PK, and relevant biomarker data.

02

Conditions studied

  • HER2-positive Breast Cancer
  • HER2-positive Gastric Cancer
  • HER2-positive Non-Small Cell Lung Cancer
  • HER2-positive Colorectal Cancer
  • HER2-positive Tumors
  • HER2 Low Breast Cancer
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's enrollment of 57 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Day One Biopharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has recurrent or solid tumors with expression and has disease progression after treatment, is intolerant to treatment, or is with available anti-cancer therapies known to confer benefit, based on investigator's judgement. Note: Participants must have HER2 positivity per the results of their most recent tumor tissue testing, defined as IHC 3+ or IHC 2+ in combination with in situ hybridization (ISH)+. Participants with ERBB2-activating mutations or ERBB2 gene amplification in the absence of HER2 positivity are considered ineligible.
  • (ECOG) performance status 0 or 1.
  • Participant must have as defined by version 1.1.
  • Participant has fresh tumor tissue available for submission to central laboratory. If obtaining fresh tumor tissue is medically contraindicated, archival tumor tissue can be submitted following written approval of the request by the study Medical Monitor. Samples must be obtained after the participant's most recent HER2-targeting therapy unless determined to be medically contraindicated after discussion with the medical monitor.

Exclusion criteria

Exclusion Criteria:

    • Participant is receiving doses of systemic medications, (doses >10 mg/day prednisone or equivalent) that cannot be discontinued for at least 2 weeks before the first dose and during study drug treatment administration. Note: physiologic hormone replacement therapy is an exception.
  • Participant has received prior treatment targeting STING pathway.
  • Diagnosis of additional that required active treatment (including surgery, systemic therapy, and radiation) within the last 2 years, expect for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the breast or the cervix. Participants with an additional malignancy that has a low risk for recurrence may be eligible after discussion with the study Medical Monitor.
  • Participants have untreated (including new and progressive brain metastases), history of , or carcinomatous meningitis.

    1. Participants are eligible if CNS metastases are adequately treated and participants are neurologically stable for at least 2 weeks prior to enrollment.
    2. In addition, participants must be either off , or on a stable/decreasing dose of ≤ 10 mg prednisone daily (or equivalent).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    XMT-2056

    XMT-2056 alone (monotherapy)

    Drug: XMT-2056

Interventions

  • DrugXMT-2056

    XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)

06

What researchers measure

Primary outcomes

  1. Frequency of dose-limiting toxicities (DLTs) associated with XMT-2056 during the first cycle of treatment (Dose Escalation)

    Determine the maximum tolerated dose (MTD) of XMT-2056

    Time frame: 15 months

  2. Incidence of adverse events (Dose Escalation and Dose Expansion)

    Assess the safety and tolerability of XMT-2056 by determining the number of patients with adverse events from date of first dose to 30 days post last dose.

    Time frame: 3 years

  3. Objective Response Rate (ORR) (Dose Expansion)

    The percentage of patients with a best overall response of confirmed complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: 3 years

Secondary outcomes

  1. Objective Response Rate (ORR) (Dose Escalation)

    The percentage of patients with a best overall response of confirmed complete or partial response as assessed by the investigator per Resist Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: 3 years

  2. Duration of response (DOR) (Dose Escalation and Dose Expansion)

    The time from when response criteria are first met until disease progression or death in participants who achieve a confirmed complete or partial response.

    Time frame: 3 years

  3. Disease control rate (DCR) (Dose Escalation and Dose Expansion)

    The percentage of patients who achieve a complete response, partial response or stable disease as the result of study treatment

    Time frame: 3 years

  4. Time of maximum observed plasma concentration of XMT-2056 (Tmax) (Dose Escalation and Dose Expansion)

    Assess the pharmacokinetics of XMT-2056

    Time frame: 3 years

  5. Maximum observed plasma concentration of XMT-2056 (Cmax) (Dose Escalation and Dose Expansion)

    Assess the pharmacokinetics of XMT-2056

    Time frame: 3 years

  6. Area under the concentration-time curve of XMT-2056 (AUC) (Dose Escalation and Dose Expansion)

    Assess the pharmacokinetics of XMT-2056

    Time frame: 3 years

  7. Systemic clearance of XMT-2056 (Dose Escalation and Dose Expansion)

    Assess the pharmacokinetics of XmT-2056 by measuring the rate at which the drug is eliminated from the body

    Time frame: 3 years

  8. Apparent terminal elimination of half-life of XMT-2056 (Dose Escalation and Dose Expansion)

    Assess the pharmacokinetics of XMT-2056

    Time frame: 3 years

  9. Volume of Distribution (Dose Escalation and Dose Expansion)

    Assess the pharmacokinetics of XMT-2056

    Time frame: 3 years

  10. Trough concentration of XMT-2056 (Ctrough) (Dose Escalation and Dose Expansion)

    Assess the pharmacokinetics of XMT-2056 by measuring the lowest concentration of drug before dosing

    Time frame: 3 years

  11. Serum samples for analysis of XMT-2056 antidrug and neutralizing antibodies (ADA/nAb) (Dose Escalation and Dose Expansion)

    Assess the development of antidrug antibodies (ADA) and neutralizing antibodies (nAB) to XMT-2056

    Time frame: 3 years

07

Study locations

14 sites
  • University of South California
    Los Angeles, California 90033, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • AdventHealth Celebration
    Celebration, Florida 34747, United States
  • Emory Healthcare, Emory Clinic
    Atlanta, Georgia 30322, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New York University Medical Oncology Associates
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43212, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in May 2026, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2022
First posted
Aug 24, 2022
StartActual
Jan 24, 2023
Primary completionActual
May 22, 2026
CompletionActual
May 22, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05514717
Lead sponsor
Day One Biopharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 24, 2022
Start date
Jan 24, 2023
Primary completion
May 22, 2026
Completion
May 22, 2026
Last update
Jun 18, 2026

Study contacts

Brad Sumrow, MD
study director · Mersana Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion